Healthcare Review: Arena Pharmaceuticals & OraSure Technologies Jump On Positive Developments Print E-mail
By Staff and Wire Reports   
Thursday, 05 July 2012 15:08
icon_MarketReportDOWNThe S&P 500 may have notched its first loss in four sessions following action from global central bankers, but healthcre investors seemed hungry to casue bullish activity in the sector during the first session back after the 4th of July holiday.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
resumed its uptrend after recent pause and soared 9.18% to $10.94. This morning, the company decided to promote Craig Audet to Senior VP, Operations and Head of Global Regulatory Affairs from VP of its regulatory affairs. The promotion was followed by the FDA’s approval of the company’s weight-loss drug Belviq. Audet's new role will also include investor relations and alliance management. Past week, the stock had strong rally as the company’s most awaited weight-loss drug Belviq won an approval from the FDA. Shares of the company have risen over 275% since early May.

OraSure Technologies, Inc. (NASDAQ:OSUR) is the biggest gainer after Tuesday's news that its home HIV test was granted by the FDA. The OraQuick In-Home HIV test has been available to healthcare professionals, but the company officials say the test will be accessible in October at retailers, large supermarket and drugstore chains, and online. Shares of the company soared 10.74% to $13.41 on heavy volume.

Geron Corporation (NASDAQ:GERN) is showing weakness in today’s session as the company Is planning to sell up to $200M of any combination of shares, debt securities and warrants. The company would use the money for working capital and general corporate purposes, including R&D. Shares of GERN slid 6.82% to $1.64.

SXC Health Solutions Corp. (NASDAQ:SXCI) rose over 2% thanks to positive note from Credit Suisse. The firm maintained its investment rating on the stock and says the next major catalyst for the company will be its earnings forecasts in its Q2 results. The vote of confidence comes after shareholders approved SXC's merger with Catalyst Health Solutions (CHSI) on Monday.

Medgenics Inc (AMEX:MDGN)
climbed over 43% after analysts Sharon di Stefano and Ray Dirks, long-time observers of new chairman, Sol Barer's career put out bullish notes on the firm. di Stefano, who watched the former chairman and CEO of Celgene Corp. (NASDAQ:CELG) build that company into a multi-billion dollar biotech powerhouse and Driks recognized the latest development at Medgenics and believe the cost-effectiveness of MDGN’s products all point to significant future shares in multiple sizeable markets. Analysts at Maxim poin out that global sales of the major products which are currently in clinical trials and which MDGN's EPODURE and INFRADURE are designed to replace, were approximately $6.9B and $2.2B in 2011.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter